0000000000330658

AUTHOR

Georgios-marios Makris

0000-0001-8945-4874

showing 4 related works from this author

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis

2018

Abstract Background Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). Materials and Methods This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian–Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed. Separate analyses were performed according to Ki-67 expression cutoff levels, invasiveness of recurrence,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsRisk Assessment03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansMeta-regressionBreastMastectomybiologybusiness.industryDuctal carcinomaPrognosismedicine.diseaseConfidence intervalCarcinoma Intraductal NoninfiltratingKi-67 Antigen030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMeta-analysisKi-67biology.proteinFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCohort studyClinical Breast Cancer
researchProduct

Gynecological adverse effects of natalizumab administration: Case report and review of the literature.

2018

Abstract Background Natalizumab is administered for the treatment of relapsing-remitting multiple sclerosis (RR-MS) with high disease activity.Natalizumab therapy has been associated with adverse effects, such as progressive multifocal leukoencephalopathy, liver damage, nasopharyngitis, urinary tract infection, urticaria, cephalgia, dizziness, fatigue, nausea, fever, rigidity, anxiety and gastroenteritis. Objective To describe a case of a woman with RR-MS who developed recurrent vaginitis on natalizumab administration. Methods Case report and review of the literature. Results The case of a 26-year-old Caucasian woman with RR-MS, who presented with recurrent vaginitis since the initiation of…

AdultPediatricsmedicine.medical_specialtyNauseaUrinary systemDisease03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingmedicineHumansImmunologic Factors030212 general & internal medicineAdverse effectVaginitisbusiness.industryProgressive multifocal leukoencephalopathyMultiple sclerosisNatalizumabGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingNeurologyFemaleNeurology (clinical)medicine.symptombusinessGenital Diseases Female030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesMultiple sclerosis and related disorders
researchProduct

Endometrial carcinoma with tibial bone metastasis: a case report and literature review.

2018

Endometrial cancer is the most common female genital malignancy and the seventh most common cause of death from cancer in women in Western countries. The median age of occurrence is 63 years, while...

OncologyFemale circumcisionmedicine.medical_specialtyBiopsy Fine-NeedleBone NeoplasmsMalignancyHysterectomyMetastasis03 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaHumansTibial boneAgedNeoplasm Staging030219 obstetrics & reproductive medicineTibiabusiness.industryEndometrial cancerObstetrics and GynecologyCancermedicine.diseaseImmunohistochemistryMagnetic Resonance ImagingEndometrial NeoplasmsChemotherapy Adjuvant030220 oncology & carcinogenesisLymph Node ExcisionFemaleRadiotherapy AdjuvantbusinessCarcinoma EndometrioidJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
researchProduct

c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients

2016

The tyrosine kinase c-met alters signaling cascades such as the BRAF-MAPK and PI3K-PKB pathways. These alterations are involved in the carcinogenesis of type I but not type II ovarian cancer (OC). Therefore, the present study investigated the patterns of c-met expression in a cohort of consecutive patients with OC. c-met expression was determined by immunohistochemical analysis. Differences in c-met overexpression among subgroups of established clinicopathological features, including age, histological subtype, tumor stage, histological grading, post-operative tumor burden and completeness of chemotherapy, were determined by χ2 test. Cox regression analyses were performed to determine the pr…

0301 basic medicineOncologyCancer ResearchPathologymedicine.medical_specialtyC-Metmedicine.medical_treatmentBiologymedicine.disease_cause03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineChemotherapyOncogeneProportional hazards modelArticlesmedicine.diseaseMolecular medicine030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisCohortCarcinogenesisOvarian cancerOncology Letters
researchProduct